ALSO NOTED: Bayer cuts 950 jobs in Berlin; CollaGenex acne drug show positive Phase II results; and much more...

> Bayer announced that it is cutting 950 jobs from its offices in Berlin as part of its integration with recently-acquired Schering. Report

> A Phase II trial of CollaGenex Pharmaceuticals' acne drug has turned in positive results in a dosing study. Release

> The FDA has approved King Pharmaceuticals' NDA for an Altace tablet formulation. Release

> Roche and KineMed have inked a deal to jointly validate KineMed's novel translational KineMarker technology. Release

And Finally… The International Narcotics Control Board (INCB) is warning that the flood of counterfeit medicines available in many countries could have fatal consequences for consumers. Release

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.